Previous 10 | Next 10 |
Dr. Pnina Fishman appointed Executive Chairman of the Board Motti Farbstein appointed Chief Executive Officer in addition to continuing as Chief Financial Officer Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipelin...
2023-04-13 08:20:45 ET CXApp ( CXAI ) +56% . Ocean Biomedical ( OCEA ) +20% a nnounces notice of allowance for U.S. patent application for developing “whole new class” of Malaria therapeutics issued to scientific co-founder Dr. Jonathan Kurtis. ...
2023-04-10 12:44:29 ET Israel-based biotech Can-Fite BioPharma ( NYSE: CANF ) added ~5% in early trading on Monday in reaction to the EU regulatory clearance over the company’s plans to conduct a pivotal study for experimental psoriasis therapy Piclidenoson. The double-...
2023-04-10 08:55:07 ET OncoSec Medical ( ONCS ) +65%.GlucoTrack ( GCTK ) +29%.Guardforce AI ( GFAI ) +22%.Eloxx Pharmaceuticals ( ELOX ) +15%.Cocrystal Pharma ( COCP ) +13% on completing $4 Million private placement priced at-the-market under Nasdaq rules.Enlivex Therape...
The Pivotal Study is Aimed to Support a Marketing Authorization Application Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today ann...
2023-03-30 07:50:38 ET Can-Fite Biopharma press release ( NYSE: CANF ): FY GAAP EPS of -$0.01. Revenue of $0.81M (-4.7% Y/Y). As of December 31, 2022, Can-Fite had cash, cash equivalents, and short-term deposits of $7.97 million as compared to $18.90 million at Decembe...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022. 2022 & Recent Cor...
Some regional deals have been already signed and include upfront money, regulatory & sales milestones, and double digit royalties Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address...
Liver organ shortage puts patients at risk of death from decompensated cirrhosis with no treatment options available Liver cirrhosis treatment market is estimated to reach approximately $15 billion in the U.S. by 2030 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TA...
Namodenoson is being evaluated in a pivotal Phase III study Namodenoson is approved for compassionate use in the treatment of liver cancer in Israel and Romania Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of pro...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...